{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"225","upperLimit":"273","value":"245"}]}],"title":"Cycle 1 (n=362)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"98","value":"91"}]}],"title":"Cycle 2 (n=363)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"98","value":"91"}]}],"title":"Cycle 3 (n=344)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"96","value":"91"}]}],"title":"Cycle 4 (n=329)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"95","value":"91"}]}],"title":"Cycle 5 (n=312)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"96","value":"91"}]}],"title":"Cycle 6 (n=303)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"95","value":"91"}]}],"title":"Cycle 7 (n=59)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90","upperLimit":"95","value":"91"}]}],"title":"Cycle 8 (n=59)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"}],"units":"Participants"}],"description":"The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"OG000","title":"Rituximab 375 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Per-protocol evaluable population: All patients who received rituximab by faster infusion in Cycle 2 and who did not experience a Grade 3 or 4 infusion-related reaction during the rituximab infusion given at the standard rate during Cycle 1.","reportingStatus":"POSTED","timeFrame":"Day 1 of each of Cycles 1 to 6 or 8","title":"Duration of Rituximab Infusion Including Dose Interruption Times","type":"SECONDARY","unitOfMeasure":"Minutes"}